Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Alessia Cimadamore, M.D.

Title
Institution
Department
Address
Phone

Biography
Università Politecnica delle Marche, AnconaMD07/2014Medicine
Bologna University, Bologna11/2019Pathology
2019 - 2020
ISUP Stipend Award

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Cheng L, Mann SA, Lopez-Beltran A, Chovanec M, Santoni M, Wang M, Albany C, Adra N, Davidson DD, Cimadamore A, Montironi R, Zhang S. Molecular Characterization of Testicular Germ Cell Tumors Using Tissue Microdissection. Methods Mol Biol. 2021; 2195:31-47. PMID: 32852755.
    Citations:    
  2. Santoni M, Massari F, Aurilio G, Mollica V, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Nolé F, Montironi R. Designing novel immunocombinations in metastatic renal cell carcinoma. Immunotherapy. 2020 Oct 01. PMID: 32998603.
    Citations:    
  3. Saoud R, Heidar NA, Cimadamore A, Paner GP. Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer. Cells. 2020 Sep 17; 9(9). PMID: 32957584.
    Citations:    
  4. Rocco B, Sighinolfi MC, Sandri M, Spandri V, Cimadamore A, Volavsek M, Mazzucchelli R, Lopez-Beltran A, Eissa A, Bertoni L, Azzoni P, Reggiani Bonetti L, Maiorana A, Puliatti S, Micali S, Paterlini M, Iseppi A, Rocco F, Pellacani G, Chester J, Bianchi G, Montironi R. Digital Biopsy with Fluorescence Confocal Microscope for Effective Real-time Diagnosis of Prostate Cancer: A Prospective, Comparative Study. Eur Urol Oncol. 2020 Sep 17. PMID: 32952095.
    Citations:    
  5. Rizzo A, Mollica V, Cimadamore A, Santoni M, Scarpelli M, Giunchi F, Cheng L, Lopez-Beltran A, Fiorentino M, Montironi R, Massari F. Is There a Role for Immunotherapy in Prostate Cancer? Cells. 2020 Sep 08; 9(9). PMID: 32911806.
    Citations:    
  6. Montironi R, Cimadamore A, Scarpelli M, Cheng L, Lopez-Beltran A, Mikuz G. Pathology without microscope: From a projection screen to a virtual slide. Pathol Res Pract. 2020 Sep 02; 216(11):153196. PMID: 32927307.
    Citations:    
  7. Rocco B, Sighinolfi MC, Cimadamore A, Reggiani Bonetti L, Bertoni L, Puliatti S, Eissa A, Spandri V, Azzoni P, Dinneen E, Shaw G, Nathan S, Micali S, Bianchi G, Maiorana A, Pellacani G, Montironi R. Digital frozen section of the prostate surface during radical prostatectomy: a novel approach to evaluate surgical margins. BJU Int. 2020 Sep; 126(3):336-338. PMID: 32401370.
    Citations:    
  8. Cimadamore A, Cheng L, Lopez-Beltran A, Mazzucchelli R, Lucianò R, Scarpelli M, Montorsi F, Montironi R. Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review. Eur Urol Oncol. 2020 Aug 31. PMID: 32883645.
    Citations:    
  9. Montironi R, Cimadamore A. Considerations on current and future issues related to reproducibility and accuracy in prostate cancer grading. Virchows Arch. 2020 Aug 17. PMID: 32808062.
    Citations:    
  10. Mollica V, Maggio I, Lopez-Beltran A, Montironi R, Cimadamore A, Cheng L, Rizzo A, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Massari F. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. Expert Rev Anticancer Ther. 2020 Sep; 20(9):755-763. PMID: 32757789.
    Citations:    
  11. Cimadamore A, Montironi R. The 1996 European Urology Focus on Preneoplastic Lesions of the Prostate. Eur Urol Focus. 2020 Aug 15. PMID: 32811780.
    Citations:    
  12. Cimadamore A, Lopez-Beltran A, Scarpelli M, Cheng L, Montironi R. Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC. J Clin Pathol. 2020 Jul 30. PMID: 32732339.
    Citations:    
  13. Aurilio G, Cimadamore A, Santoni M, Nolè F, Scarpelli M, Massari F, Lopez-Beltran A, Cheng L, Montironi R. New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? Cells. 2020 Jun 22; 9(6). PMID: 32580469.
    Citations:    
  14. Cantini L, Pecci F, Murrone A, Tomasetti M, Copparoni C, Fiordoliva I, Morgese F, Rinaldi S, Mazzanti P, Rubini C, Cimadamore A, Barbisan F, Giampieri R, Scarpelli M, Santarelli L, Berardi R. Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis. Lung Cancer. 2020 Aug; 146:318-326. PMID: 32622302.
    Citations:    
  15. Cimadamore A, Aurilio G, Nolé F, Massari F, Scarpelli M, Santoni M, Lopez-Beltran A, Cheng L, Montironi R. Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. Cells. 2020 Jun 19; 9(6). PMID: 32575429.
    Citations:    
  16. Santoni M, Massari F, Cheng L, Cimadamore A, Scarpelli M, Montironi R, Lopez-Beltran A. PD-L1 inhibitors for the treatment of prostate cancer. Curr Drug Targets. 2020 Jun 09. PMID: 32516098.
    Citations:    
  17. Raspollini MR, Montagnani I, Cirri P, Baroni G, Cimadamore A, Scarpelli M, Cheng L, Lopez-Beltran A, Montironi R, Barnea ER. PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness. Int J Biol Markers. 2020 Jun; 35(2):82-90. PMID: 32389051.
    Citations:    
  18. Montironi R, Cheng L, Cimadamore A, Lopez-Beltran A, Scarpelli M. Uropathologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance. Eur Urol. 2020 09; 78(3):478-481. PMID: 32416977.
    Citations:    
  19. Gevaert T, Cimadamore A, Montironi R, Eckstein M. PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives. Curr Drug Targets. 2020 May 09. PMID: 32386490.
    Citations:    
  20. Montironi R, Cimadamore A, Lopez-Beltran A, Scarpelli M, Aurilio G, Santoni M, Massari F, Cheng L. Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. Cells. 2020 Apr 25; 9(5). PMID: 32344931.
    Citations:    
  21. Raspollini MR, Montironi R, Mazzucchelli R, Cimadamore A, Cheng L, Lopez-Beltran A. pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging. Virchows Arch. 2020 Jul; 477(1):3-16. PMID: 32296929.
    Citations:    
  22. Occhipinti G, Romagnoli E, Santoni M, Cimadamore A, Sorgentoni G, Cecati M, Giulietti M, Battelli N, Maccioni A, Storti N, Cheng L, Principato G, Montironi R, Piva F. Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications. Front Genet. 2020; 11:349. PMID: 32351542.
    Citations:    
  23. Montironi R, Cimadamore A, Scarpelli M. From Undergraduate Medical School Student to Visible Pathologist. Arch Pathol Lab Med. 2020 04; 144(4):413-414. PMID: 32233991.
    Citations:    
  24. Cimadamore A, Massari F, Santoni M, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Moch H. PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay. Curr Drug Targets. 2020 Mar 24. PMID: 32208115.
    Citations:    
  25. Montironi R, Cimadamore A, Ohashi R, Cheng L, Scarpelli M, Lopez-Beltran A, Moch H. Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One. Eur Urol Oncol. 2020 Mar 18. PMID: 32199916.
    Citations:    
  26. Mollica V, Santoni M, Di Nunno V, Cimadamore A, Cheng L, Lopez-Beltran A, Battelli N, Montironi R, Massari F. Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. Curr Drug Targets. 2020 Mar 11. PMID: 32160846.
    Citations:    
  27. Cimadamore A, Cheng L, Ohashi R, Scarpelli M, Lopez-Beltran A, Moch H, Montironi R. Re: Multi-institutional Re-evaluation of Prognostic Factors in Chromophobe Renal Cell Carcinoma: Proposal of a Novel Two-tiered Grading Scheme. Eur Urol. 2020 Jul; 78(1):114-116. PMID: 32143925.
    Citations:    
  28. Cimadamore A, Scarpelli M, Massari F, Eckstein M, Gevaert T, Cheng L, Lopez-Beltran A, Montironi R. Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view. Expert Opin Biol Ther. 2020 Jun; 20(6):539-544. PMID: 32081061.
    Citations:    
  29. Cimadamore A, Scarpelli M, Cheng L, Lopez-Beltran A, Galosi AB, Montorsi F, Montironi R. Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019;76:871. Eur Urol. 2020 May; 77(5):e122-e127. PMID: 32089357.
    Citations:    
  30. Rocco B, Sighinolfi MC, Bertoni L, Spandri V, Puliatti S, Eissa A, Reggiani Bonetti L, Azzoni P, Sandri M, De Carne C, Turri F, Cimadamore A, Montironi R, Maiorana A, Micali S, Bianchi G, Pellacani G. Real-time assessment of surgical margins during radical prostatectomy: a novel approach that uses fluorescence confocal microscopy for the evaluation of peri-prostatic soft tissue. BJU Int. 2020 04; 125(4):487-489. PMID: 31971342.
    Citations:    
  31. Montironi R, Cheng L, Cimadamore A, Lopez-Beltran A. Molecular diagnostics in uro-oncology. Expert Rev Mol Diagn. 2020 02; 20(2):117-121. PMID: 31933387.
    Citations:    
  32. Rolim I, Henriques V, Rolim N, Blanca A, Marques RC, Volavšek M, Carvalho I, Montironi R, Cimadamore A, Raspollini MR, Cheng L, Lopez-Beltran A. Clinicopathologic analysis of upper urinary tract carcinoma with variant histology. Virchows Arch. 2020 Jul; 477(1):111-120. PMID: 31950242.
    Citations:    
  33. Cimadamore A, Lopez-Beltran A, Massari F, Santoni M, Mazzucchelli R, Scarpelli M, Galosi AB, Cheng L, Montironi R. Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy. Future Oncol. 2020 Feb; 16(5):75-80. PMID: 31916449.
    Citations:    
  34. Santoni M, Heng DYC, Aurilio G, Iozzelli A, Servi L, Fabiani A, Giannini M, Mazzucchelli R, Cimadamore A, Scarpelli M, Zaghloul MS, Battelli N, Montironi R. Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma. Curr Drug Targets. 2020; 21(4):416-423. PMID: 31625471.
    Citations:    
  35. Santoni M, Heng DY, Bracarda S, Procopio G, Milella M, Porta C, Matrana MR, Cartenì G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A, Cheng L, Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, Verzoni E, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, Cimadamore A, Montironi R, Battelli N. Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. Cancers (Basel). 2019 Dec 30; 12(1). PMID: 31905816.
    Citations:    
  36. Santoni M, Conti A, Massari F, Di Nunno V, Faloppi L, Galizia E, Morbiducci J, Piva F, Buti S, Iacovelli R, Ferretti B, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, Battelli N, Montironi R. Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. Expert Rev Cardiovasc Ther. 2019 Dec; 17(12):917-927. PMID: 31829045.
    Citations:    
  37. Lopez-Beltran A, Cheng L, Gevaert T, Blanca A, Cimadamore A, Santoni M, Massari F, Scarpelli M, Raspollini MR, Montironi R. Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers. Expert Rev Mol Diagn. 2020 02; 20(2):231-243. PMID: 31795775.
    Citations:    
  38. Aurilio G, Piva F, Santoni M, Cimadamore A, Sorgentoni G, Lopez-Beltran A, Cheng L, Battelli N, Nolè F, Montironi R. The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications. Int J Mol Sci. 2019 Nov 13; 20(22). PMID: 31766196.
    Citations:    
  39. Eckstein M, Cimadamore A, Hartmann A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Gevaert T. PD-L1 assessment in urothelial carcinoma: a practical approach. Ann Transl Med. 2019 Nov; 7(22):690. PMID: 31930091.
    Citations:    
  40. Massari F, Nunno VD, Mollica V, Montironi R, Cheng L, Cimadamore A, Blanca A, Lopez-Beltran A. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy. 2019 12; 11(17):1507-1521. PMID: 31663411.
    Citations:    
  41. Mollica V, Di Nunno V, Santoni M, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, Mariani C, Battelli N, Montironi R, Massari F. An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. Expert Rev Mol Diagn. 2020 02; 20(2):207-217. PMID: 31640441.
    Citations:    
  42. Kouba E, Lopez-Beltran A, Montironi R, Massari F, Huang K, Santoni M, Chovanec M, Cheng M, Scarpelli M, Zhang J, Cimadamore A, Cheng L. Liquid biopsy in the clinical management of bladder cancer: current status and future developments. Expert Rev Mol Diagn. 2020 02; 20(2):255-264. PMID: 31608720.
    Citations:    
  43. Volavšek M, Henriques V, Blanca A, Montironi R, Cheng L, Raspollini MR, Cimadamore A, Vau N, Pierconti F, Lopez-Beltran A. Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples. Virchows Arch. 2019 Dec; 475(6):735-744. PMID: 31588959.
    Citations:    
  44. Cimadamore A, Scarpelli M, Raspollini MR, Doria A, Galosi AB, Massari F, Di Nunno V, Cheng L, Lopez-Beltran A, Montironi R. Prostate cancer pathology: What has changed in the last 5 years. Urologia. 2020 Feb; 87(1):3-10. PMID: 31545701.
    Citations:    
  45. Cimadamore A, Massari F, Santoni M, Mollica V, Di Nunno V, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R, Moch H. Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. Expert Rev Mol Diagn. 2020 02; 20(2):141-150. PMID: 31498685.
    Citations:    
  46. Cimadamore A, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Liquid biopsies in renal cell carcinoma with focus on epigenome analysis. Ann Transl Med. 2019 Sep; 7(Suppl 6):S194. PMID: 31656773.
    Citations:    
  47. Santoni M, Cimadamore A, Massari F, Piva F, Aurilio G, Martignetti A, Scarpelli M, Di Nunno V, Gatto L, Battelli N, Cheng L, Lopez-Beltran A, Montironi R. Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. Cancers (Basel). 2019 Aug 22; 11(9). PMID: 31443386.
    Citations:    
  48. Vau N, Henriques V, Cheng L, Blanca A, Fonseca J, Montironi R, Cimadamore A, Lopez-Beltran A. Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule. Hum Pathol. 2019 11; 93:6-15. PMID: 31442520.
    Citations:    
  49. Cimadamore A, Scarpelli M, Cheng L, Lopez-Beltran A, Montorsi F, Montironi R. Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol 2019;76:27-30: Morphologic Documentation from Didactic Cases of Large-format Histology. Eur Urol. 2020 Apr; 77(4):e100-e102. PMID: 31420247.
    Citations:    
  50. Blanca A, Sanchez-Gonzalez A, Requena MJ, Carrasco-Valiente J, Gomez-Gomez E, Cheng L, Cimadamore A, Montironi R, Lopez-Beltran A. Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer. APMIS. 2019 Aug; 127(8):545-553. PMID: 31231851.
    Citations:    
  51. Di Nunno V, Massari F, Mollica V, Cimadamore A, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma. Ann Transl Med. 2019 Jul; 7(Suppl 3):S137. PMID: 31576344.
    Citations:    
  52. Rebola J, Aguiar P, Blanca A, Montironi R, Cimadamore A, Cheng L, Henriques V, Lobato-Faria P, Lopez-Beltran A. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype. Virchows Arch. 2019 Oct; 475(4):445-455. PMID: 31240474.
    Citations:    
  53. Gevaert T, Cimadamore A, Eckstein M, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R. Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go. Future Oncol. 2019 Jul; 15(19):2199-2202. PMID: 31213082.
    Citations:    
  54. Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Montironi R, Massari F. Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. Cancers (Basel). 2019 Jun 14; 11(6). PMID: 31207938.
    Citations:    
  55. Montironi R, Cheng L, Scarpelli M, Cimadamore A, Montorsi F, Lopez-Beltran A. Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream? Eur Urol. 2019 09; 76(3):e69-e72. PMID: 31176624.
    Citations:    
  56. Mollica V, Di Nunno V, Gatto L, Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Montironi R, Pisconti S, Battelli N, Massari F. Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. Clin Drug Investig. 2019 Jun; 39(6):503-519. PMID: 30937824.
    Citations:    
  57. Montironi R, Santoni M, Cimadamore A, Lopez-Beltran A, Cheng L. Editorial: Emerging Biomarkers in Genitourinary Tumors. Front Oncol. 2019; 9:326. PMID: 31106155.
    Citations:    
  58. Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Scarpelli M, Galosi AB, Bracarda S, Montironi R. Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. Front Oncol. 2019; 9:228. PMID: 31024837.
    Citations:    
  59. Massari F, Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Montironi R, Brandi G. The Human Microbiota and Prostate Cancer: Friend or Foe? Cancers (Basel). 2019 Mar 31; 11(4). PMID: 30935126.
    Citations:    
  60. Cimadamore A, Santoni M, Massari F, Gasparrini S, Cheng L, Lopez-Beltran A, Montironi R, Scarpelli M. Microbiome and Cancers, With Focus on Genitourinary Tumors. Front Oncol. 2019; 9:178. PMID: 30972292.
    Citations:    
  61. Cimadamore A, Palagonia E, Piccinni P, Misericordia M, Galosi AB, Montironi R. Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer. Urologia. 2019 Feb; 86(1):35-38. PMID: 30808261.
    Citations:    
  62. Cimadamore A, Gasparrini S, Massari F, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. Cancers (Basel). 2019 Feb 07; 11(2). PMID: 30736478.
    Citations:    
  63. Mollica V, Di Nunno V, Cimadamore A, Lopez-Beltran A, Cheng L, Santoni M, Scarpelli M, Montironi R, Massari F. Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. Cells. 2019 01 11; 8(1). PMID: 30642011.
    Citations:    
  64. Bianconi M, Cimadamore A, Faloppi L, Scartozzi M, Santoni M, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R. Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. Ther Adv Urol. 2019 Jan-Dec; 11:1756287218815372. PMID: 30671136.
    Citations:    
  65. Lopez-Beltran A, Henriques V, Montironi R, Cimadamore A, Raspollini MR, Cheng L. Variants and new entities of bladder cancer. Histopathology. 2019 Jan; 74(1):77-96. PMID: 30565299.
    Citations:    
  66. Cimadamore A, Scarpelli M, Santoni M, Massari F, Tartari F, Cerqueti R, Lopez-Beltran A, Cheng L, Montironi R. Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. Curr Drug Metab. 2019; 20(4):305-312. PMID: 30799789.
    Citations:    
  67. Cimadamore A, Cheng M, Santoni M, Lopez-Beltran A, Battelli N, Massari F, Galosi AB, Scarpelli M, Montironi R. New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen. Front Oncol. 2018; 8:653. PMID: 30622933.
    Citations:    
  68. Chovanec M, Albany C, Mego M, Montironi R, Cimadamore A, Cheng L. Emerging Prognostic Biomarkers in Testicular Germ Cell Tumors: Looking Beyond Established Practice. Front Oncol. 2018; 8:571. PMID: 30547014.
    Citations:    
  69. Cimadamore A, Scarpelli M, Santoni M, Cheng L, Lopez-Beltran A, Montironi R. Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapy. Expert Rev Mol Diagn. 2018 12; 18(12):1021-1028. PMID: 30452305.
    Citations:    
  70. Cimadamore A, Scarpelli M, Santoni M, Cheng L, Lopez-Beltran A, Montorsi F, Montironi R. Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vasc Interv Radiol 2018;29:589-97. Eur Urol 2018;74:525-6: Could Morphologic Changes in Periprostatic Arteries Have an Influence on Prostatic Artery Embolization? Eur Urol. 2019 04; 75(4):e110-e113. PMID: 30471886.
    Citations:    
  71. Saeed O, Lopez-Beltran A, Fisher KW, Scarpelli M, Montironi R, Cimadamore A, Massari F, Santoni M, Cheng L. RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. J Clin Pathol. 2019 Feb; 72(2):135-139. PMID: 30425122.
    Citations:    
  72. Lopez-Beltran A, Henriques V, Cimadamore A, Santoni M, Cheng L, Gevaert T, Blanca A, Massari F, Scarpelli M, Montironi R. The Identification of Immunological Biomarkers in Kidney Cancers. Front Oncol. 2018; 8:456. PMID: 30450335.
    Citations:    
  73. Giunchi F, Cimadamore A, Fiorentino M. Emerging Molecular Technologies in Genitourinary Tumors. Front Oncol. 2018; 8:489. PMID: 30425967.
    Citations:    
  74. Di Nunno V, Gatto L, Santoni M, Cimadamore A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Massari F. Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. Front Oncol. 2018; 8:397. PMID: 30319966.
    Citations:    
  75. Di Nunno V, Cimadamore A, Santoni M, Scarpelli M, Fiorentino M, Ciccarese C, Iacovelli R, Cheng L, Lopez-Beltran A, Massari F, Montironi R. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. Future Oncol. 2018 Oct; 14(25):2559-2564. PMID: 30141348.
    Citations:    Fields:    
  76. Montironi R, Cheng L, Cimadamore A, Lopez-Beltran A. Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2? Eur Urol. 2019 01; 75(1):32-34. PMID: 30093172.
    Citations:    
  77. Cimadamore A, Scarpelli M, Cheng L, Lopez-Beltran A, Montorsi F, Montironi R. Re: Isabel Rauscher, Charlotte Düwel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. Eur Urol 2018;73:656-61: Clinical Significance of Prostate-specific Membrane Antigen Immunohistochemistry and Role of the Uropathologists. Eur Urol. 2018 12; 74(6):e141-e144. PMID: 30093173.
    Citations:    
  78. Di Nunno V, Santoni M, Cimadamore A, Battelli N, Massari F. Re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin. Updates in the Eighth Edition of the Tumor-node-metastasis Staging Classification for Urologic Cancers. Eur Urol 2018;73:560-9: Tumour, Node, and Metastasis Staging System for Urological Malignancies: Are We Ready for the Next Step? Eur Urol. 2018 11; 74(5):e118-e119. PMID: 30017397.
    Citations:    
  79. Cimadamore A, Gasparrini S, Santoni M, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Giunchi F, Fiorentino M, Scarpelli M, Montironi R. Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. Expert Rev Mol Diagn. 2018 07; 18(7):645-655. PMID: 29912582.
    Citations: 1     Fields:    
  80. Montironi R, Cimadamore A, Cheng L, Lopez-Beltran A, Scarpelli M. Prostate cancer grading in 2018: limitations, implementations, cribriform morphology, and biological markers. Int J Biol Markers. 2018 Nov; 33(4):331-334. PMID: 29945478.
    Citations:    
  81. Giulietti M, Santoni M, Cimadamore A, Carrozza F, Piva F, Cheng L, Lopez-Beltran A, Scarpelli M, Battelli N, Montironi R. Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer. Front Oncol. 2018; 8:221. PMID: 29951374.
    Citations:    
  82. Santoni M, Piva F, Conti A, Santoni A, Cimadamore A, Scarpelli M, Battelli N, Montironi R. Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial Tumors. Eur Urol. 2018 10; 74(4):521-522. PMID: 29891391.
    Citations:    
  83. Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M, Montironi R, Cheng L, Battelli N, Lopez-Beltran A. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs Context. 2018; 7:212528. PMID: 29899754.
    Citations:    
  84. Massari F, Santoni M, di Nunno V, Cheng L, Lopez-Beltran A, Cimadamore A, Gasparrini S, Scarpelli M, Battelli N, Montironi R. Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. Cancer Treat Rev. 2018 Jul; 68:80-85. PMID: 29886353.
    Citations:    
  85. Santoni M, Massari F, Piva F, Carrozza F, Di Nunno V, Cimadamore A, Martignetti A, Montironi R, Battelli N. Tivozanib for the treatment of renal cell carcinoma. Expert Opin Pharmacother. 2018 Jun; 19(9):1021-1025. PMID: 29851529.
    Citations:    
  86. Cimadamore A, Scarpelli M, Cheng L, Lopez-Beltran A, Montironi R. Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion. Minerva Urol Nefrol. 2019 04; 71(2):189-190. PMID: 29761691.
    Citations:    
  87. Montironi R, Cimadamore A, Gasparrini S, Mazzucchelli R, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M. Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. Expert Rev Anticancer Ther. 2018 07; 18(7):685-693. PMID: 29699428.
    Citations:    
  88. Meletani T, Cantini L, Lanese A, Nicolini D, Cimadamore A, Agostini A, Ricci G, Antognoli S, Mandolesi A, Guido M, Alaggio R, Giuseppetti GM, Scarpelli M, Vivarelli M, Berardi R. Are liver nested stromal epithelial tumors always low aggressive? World J Gastroenterol. 2017 Dec 14; 23(46):8248-8255. PMID: 29290661.
    Citations:    
  89. Cimadamore A, Gasparrini S, Mazzucchelli R, Doria A, Cheng L, Lopez-Beltran A, Santoni M, Scarpelli M, Montironi R. Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression. Front Oncol. 2017; 7:305. PMID: 29312884.
    Citations:    
  90. Montironi R, Cimadamore A, Massari F, Montironi MA, Lopez-Beltran A, Cheng L, Montorsi F, Scarpelli M. Whole Slide Imaging of Large Format Histology in Prostate Pathology: Potential for Information Fusion. Arch Pathol Lab Med. 2017 11; 141(11):1460-1461. PMID: 29072947.
    Citations:    
  91. Gasparrini S, Cimadamore A, Scarpelli M, Massari F, Doria A, Mazzucchelli R, Cheng L, Lopez-Beltran A, Montironi R. Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. Asian J Androl. 2017 Aug 04. PMID: 28782737.
    Citations:    
  92. Gasparrini S, Cimadamore A, Mazzucchelli R, Scarpelli M, Massari F, Raspollini MR, Galosi AB, Lopez-Beltran A, Cheng L, Montironi R. Pathology and molecular updates in tumors of the prostate: towards a personalized approach. Expert Rev Mol Diagn. 2017 08; 17(8):781-789. PMID: 28598696.
    Citations:    
  93. Cimadamore A, Scarpelli M, Piva F, Massari F, Gasparrini S, Doria A, Cheng L, Lopez-Beltran A, Montironi R. Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets. Future Oncol. 2017 May; 13(12):1105-1114. PMID: 28147707.
    Citations:    
  94. Cimadamore A, Gasparrini S, Scarpelli M, Doria A, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A, Montironi R. Epigenetic Modifications and Modulators in Prostate Cancer. Crit Rev Oncog. 2017; 22(5-6):439-450. PMID: 29604923.
    Citations:    
  95. Guerra E, Cimadamore A, Simeone P, Vacca G, Lattanzio R, Botti G, Gatta V, D'Aurora M, Simionati B, Piantelli M, Alberti S. p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading. BMC Cancer. 2016 08 18; 16:649. PMID: 27538498.
    Citations:    
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Cimadamore's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (138)
Explore
_
Co-Authors (1)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.